Seres Therapeutics is a microbiome therapeutics company that was founded in 2010 and headquartered in Cambridge, Massachusetts.
On November 27, 2012 Seres Therapeutics closed their series A funding round with an undisclosed amount of funding from Flagship Pioneering and Enso Ventures.
On may 23, 2014 Seres Therapeutics closed their series B funding round with$10 million in funding from Mayo Clinic, Flagship Pioneering, Enso ventures, and Alexandria Venture.
On December 2, 2014 Seres Therapeutics closed their series C funding round with $48 million in funding from Flagship Pioneering.
On January 6, 2015 Seres Therapeutics closed their series D funding round with $65 million in funding from Nestlé Health Science.